Vineet MBA - Frequency Therapeutics Chief Officer
| KRRO Stock | 54.99 1.74 3.27% |
Executive
Vineet MBA is Chief Officer of Frequency Therapeutics
| Age | 42 |
| Address | One Kendall Square, Cambridge, MA, United States, 02139 |
| Phone | 617 468 1999 |
| Web | https://www.korrobio.com |
Frequency Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3527) % which means that it has lost $0.3527 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7451) %, meaning that it created substantial loss on money invested by shareholders. Frequency Therapeutics' management efficiency ratios could be used to measure how well Frequency Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to drop to -0.44. At this time, Frequency Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 2.8 M, while Total Assets are likely to drop about 153.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anthony LeHan | Siriuspoint | 63 | |
| Bradley Lerman | Starbucks | 67 | |
| Albert Perley | Barings BDC | N/A | |
| Justin Brenden | Siriuspoint | 40 | |
| Karen Caddick | Siriuspoint | 55 | |
| Alaxandar Wang | Uber Technologies | N/A | |
| Susan Anderson | Uber Technologies | N/A | |
| James McKinney | Siriuspoint | 44 | |
| Alexandra Pacini | Barings BDC | 32 | |
| Ronald Sugar | Uber Technologies | 72 | |
| Andy Adams | Starbucks | N/A | |
| Janet Landers | Starbucks | N/A | |
| Keith Correia | Portillos | 52 | |
| Adam Wudel | Summit Hotel Properties | N/A | |
| Sean Walters | Datadog | 51 | |
| Yanbing Li | Datadog | 53 | |
| Kelly Kaiser | Portillos | 49 | |
| Brady Brewer | Starbucks | 51 | |
| David Galloreese | Datadog | 44 | |
| Jan Onselius | Siriuspoint | 67 | |
| Christopher JD | Summit Hotel Properties | 53 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 |
Frequency Therapeutics Leadership Team
Elected by the shareholders, the Frequency Therapeutics' board of directors comprises two types of representatives: Frequency Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Frequency. The board's role is to monitor Frequency Therapeutics' management team and ensure that shareholders' interests are well served. Frequency Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Frequency Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Fraley, CoFounder Advisor | ||
| Shelby JD, Senior Counsel | ||
| Vineet MBA, Chief Officer | ||
| Ravi Ramadas, Vice Development | ||
| Steven Colletti, Chief Officer | ||
| Joshua Rosenthal, CoFounder Advisor | ||
| Todd MBA, Chief Officer | ||
| MBA MD, CoFounder Director | ||
| Venkat Krishnamurthy, Senior Platform | ||
| Josh Rosenthal, CoFounder Advisor | ||
| Stephanie Engels, Senior Culture | ||
| Nessan Bermingham, CoFounder Chairman | ||
| Marco Passini, VP biology | ||
| Todd Chappell, Chief Officer | ||
| PharmD JD, Senior Counsel | ||
| Ram MBA, President CEO |
Frequency Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Frequency Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 419.95 M | ||||
| Shares Outstanding | 9.37 M | ||||
| Shares Owned By Insiders | 6.44 % | ||||
| Shares Owned By Institutions | 91.37 % | ||||
| Number Of Shares Shorted | 244.85 K | ||||
| Price To Book | 2.87 X | ||||
| EBITDA | (80.9 M) | ||||
| Net Income | (81.17 M) |
Pair Trading with Frequency Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Frequency Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Frequency Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Frequency Stock
Moving against Frequency Stock
| 0.65 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
| 0.6 | HLN | Haleon plc | PairCorr |
| 0.53 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.49 | ZTS | Zoetis Inc | PairCorr |
| 0.47 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Frequency Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Frequency Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Frequency Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Frequency Therapeutics to buy it.
The correlation of Frequency Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Frequency Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Frequency Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Frequency Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Frequency Therapeutics. If investors know Frequency will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Frequency Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.43) | Return On Assets (0.35) | Return On Equity (0.75) |
The market value of Frequency Therapeutics is measured differently than its book value, which is the value of Frequency that is recorded on the company's balance sheet. Investors also form their own opinion of Frequency Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Frequency Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Frequency Therapeutics' market value can be influenced by many factors that don't directly affect Frequency Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Frequency Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Frequency Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Frequency Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.